<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61237</article-id><article-id pub-id-type="doi">10.17816/dv61237</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL PICTURE, DIAGNOSIS, AND THERAPY OF DERMATOSES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИКА, ДИАГНОСТИКА И ЛЕЧЕНИЕ ДЕРМАТОЗОВ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Optimization of the molecular genetics for the diagnosis of early mycosis fungoides</article-title><trans-title-group xml:lang="ru"><trans-title>Оптимизация молекулярно-генетического метода диагностики ранних стадий грибовидного микоза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2482-1754</contrib-id><contrib-id contrib-id-type="spin">2500-7989</contrib-id><name-alternatives><name xml:lang="en"><surname>Olisova</surname><given-names>Olga Yu.</given-names></name><name xml:lang="ru"><surname>Олисова</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>olisovaolga@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7968-9829</contrib-id><contrib-id contrib-id-type="spin">8028-5545</contrib-id><name-alternatives><name xml:lang="en"><surname>Grekova</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Грекова</surname><given-names>Екатерина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant, Professor</p></bio><bio xml:lang="ru"><p>ассистент</p></bio><email>grekova_kate@mail.ru</email><uri>https://journals.eco-vector.com/1560-9588/user/registerUser#formErrors</uri><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseeva</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Алексеева</surname><given-names>Екатерина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biol.), Senior Research Associate</p></bio><bio xml:lang="ru"><p>к.б.н., ст. науч.сотр.</p></bio><email>ekater.alekseeva@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9323-2673</contrib-id><contrib-id contrib-id-type="spin">9836-2326</contrib-id><name-alternatives><name xml:lang="en"><surname>Zaletaev</surname><given-names>Dmitry V.</given-names></name><name xml:lang="ru"><surname>Залетаев</surname><given-names>Дмитрий Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biol.), Professor</p></bio><bio xml:lang="ru"><p>д.б.н., профессор</p></bio><email>zalnem@mail.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M.Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Centre for Medical Genetics</institution></aff><aff><institution xml:lang="ru">Медико-генетический научный центр имени академика Н.П. Бочкова</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M.Sechenov First Moscow State Medical University (Sechenov University), Research Centre for Medical Genetics</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff id="aff4"><institution>Медико-генетический научный центр имени академика Н.П. Бочкова</institution></aff><pub-date date-type="pub" iso-8601-date="2021-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2021</year></pub-date><volume>24</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>35</fpage><lpage>44</lpage><history><date date-type="received" iso-8601-date="2021-02-18"><day>18</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-03-17"><day>17</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Эко-Вектор"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2025-08-01"/></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/61237">https://rjsvd.com/1560-9588/article/view/61237</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND: </italic></bold>Mycosis fungoides (MF) is the most common disease among the cutaneous T-cell lymphomas (85–90%). The accuracy of the diagnosis of MF, which is confirmed only by clinical, histological and immunohistochemical signs, is 50–75%.</p> <p><bold><italic>AIMS: </italic></bold>To investigate genetic marker <italic>STAT4</italic> for early diagnosis of mycosis fungoides.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold> A study involving 42 patients with MF and chronic benign dermatoses (CBD) was performed. The analysis of gene expression <italic>STAT4</italic> was carried out by TaqMan Real time-PCR. The objects of the study were lesional skin samples of patients. A group with MF consisted of 29 patients, a group with CBD consisted of 13 patients, a control group included 10 healthy volunteers.</p> <p><bold><italic>RESULTS: </italic></bold>The study revealed that the level of <italic>STAT4</italic> gene expression showed a significant (9 times) increase in the expression of gene <italic>STAT4 </italic>in patients with MF (168.2) compared with patients with CBD (18.5; <italic>p</italic> &lt;0.001) and 561 times — with healthy volunteers (0.3; <italic>p</italic> &lt;0.001).</p> <p><bold><italic>CONCLUSION</italic><italic>:</italic></bold> For early diagnosis of MF the level of expression <italic>STAT4</italic> is of great importance. Inclusion of <italic>STAT4</italic> in the list of diagnostic algorithm increases the accuracy of differential diagnosis of MF and CBD from 59.1 to 92.2%.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование.</italic></bold> Грибовидный микоз (ГМ) среди Т-клеточных лимфом кожи встречается наиболее часто (85–90%). Достоверность диагноза ГМ, подтверждённого только клиническими, гистологическими и иммуногистохимическими признаками, составляет 50–75%.</p> <p><bold><italic>Цель</italic></bold> — изучение уровня экспрессии генетического маркера STAT4 для ранней диагностики ГМ.</p> <p><bold><italic>Материал и методы.</italic></bold> Под нашим наблюдением находилось 42 пациента, из них 29 страдали ГМ, 13 — хроническими доброкачественными дерматозами (ХДД). Группу контроля составили 10 здоровых лиц. Анализ экспрессии гена <italic>STAT4</italic> проводили методом полимеразной цепной реакции с флуоресцентной детекцией TaqMan в режиме реального времени (ПЦР-РВ). Объектами исследования были поражённые участки кожи больных ГМ, ХДД и здоровых лиц.</p> <p><bold><italic>Результаты. </italic></bold>В ходе исследования выявлено, что уровень экспрессии гена <italic>STAT4</italic> был значительно (в 9 раз) повышен у больных ГМ (168,2 отн. ед.) в сравнении с больными ХДД (18,5 отн. ед.; <italic>p</italic> &lt;0,001) и в 561 раз ― в сравнении со здоровыми лицами (0,3 отн. ед.; <italic>p</italic> &lt;0,001).</p> <p><bold><italic>Заключение.</italic></bold> Уровень экспрессии гена <italic>STAT4</italic> приобретает всё большее значение для ранней диагностики ГМ. Включение <italic>STAT4</italic> в диагностический алгоритм повышает точность дифференциальной диагностики ГМ и ХДД с 59,1 до 92,2%.</p></trans-abstract><kwd-group xml:lang="en"><kwd>mycosis fungoides</kwd><kwd>early diagnosis</kwd><kwd>STAT4</kwd><kwd>qPCR</kwd><kwd>molecular genetic method of diagnosis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>грибовидный микоз</kwd><kwd>ранняя диагностика</kwd><kwd>STAT4</kwd><kwd>ПЦР-РВ</kwd><kwd>молекулярно-генетический метод диагностики</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Poddubnaya IV, Savchenko VG, eds. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow : MMA MediaMedika; 2014. 128 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Поддубная И.В., Савченко В.Г., ред. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Москва : ММА МедиаМедика, 2014. 128 с.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Rodd AL, Ververis K, Karagiannis TC. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012;2012:1–10. doi: 10.1155/2012/290685</mixed-citation><mixed-citation xml:lang="ru">Rodd A.L., Ververis K., Karagiannis T.C. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors // Lymphoma. 2012. Vol. 2012. Р. 1–10. doi: 10.1155/2012/290685</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Alibert JL. Description des maladies de la peau. Barrois l’aine et Fils; 1806. (In French).</mixed-citation><mixed-citation xml:lang="ru">Alibert J.L. Description des maladies de la peau. Vol. 113. Barrois l’aine et Fils; 1806.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Zaslavskiy DV, Sydikov AA, Zaytsev BC, et al. Detection of antigen of herpes simplex virus types 1,2, human papilloma and Epstein–Barr in patients with large-and small-plaque parapsoriasis. Problems in Medical Mycology. 2013;15(2):78. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Заславский Д.В., Сыдиков A.A., Зайцев B.C. и др. Выявление антигена вирусов простого герпеса I, II типов, папилломы человека и Эпштейна–Барр у больных крупно- и мелкобляшечным парапсориазом // Проблемы медицинской микологии. 2013. Т. 15, № 2. С. 78.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Bratseva EV, Rotanov CV. Current approaches to diagnostics of mycosis fungoides. Vestnik dermatologii i venerologii. 2010;(6):16–22. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Братцева Е.В., Ротанов C.В. Современные подходы к диагностике грибовидного микоза // Вестник дерматологии и венерологии. 2010. № 6. С. 16–22.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Olisova OYu, Vladimirova EV, Babushkin AM. The skin and the sun. Russian Journal of Skin and Venereal Diseases. 2012;15(6):57–62. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Олисова О.Ю., Владимирова Е.В., Бабушкин А.М. Кожа и солнце // Российский журнал кожных и венерических болезней. 2012. Т. 15(6). С. 57–62.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Johnson VE, Vonderheid EC, Hess AD, et al. Genetic markers associated with progression in early mycosis fungoides. J Eur Acad Dermatol Venereol. 2014;28(11):1431–1435. doi: 10.1111/jdv.12299</mixed-citation><mixed-citation xml:lang="ru">Johnson V.E., Vonderheid E.C., Hess A.D., et al. Genetic markers associated with progression in early mycosis fungoides // J Eur Acad Dermatol Venereol. 2014. Vol. 28, N 11. Р. 1431–1435. doi: 10.1111/jdv.12299</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–2607. doi: 10.1200/JCO.2010.32.0630</mixed-citation><mixed-citation xml:lang="ru">Olsen E.A., Whittaker S., Kim Y.H., et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer // J Clin Oncol. 2011. Vol. 29, N 18. Р. 2598–2607. doi: 10.1200/JCO.2010.32.0630</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Belousova IE. Federal clinical guidelines for the management of patients with skin lymphomas. Moscow; 2015. 37 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Белоусова И.Э. Федеральные клинические рекомендации по ведению больных лимфомами кожи. Москва, 2015.37 с.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Kungurov NV, Malishevskaya NP, Kokhan MM, et al. Malignant neoplasms of the skin: morbidity, diagnostic errors, organization of early detection, prevention. Kurgan : Zauralie; 2010. Р. 13–15. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Кунгуров Н.В., Малишевская Н.П., Кохан М.М. и др. Злокачественные новообразования кожи: заболеваемость, ошибки диагностики, организация раннего выявления, профилактика. Курган : Зауралье; 2010. С. 13–15.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Bernier C, Nguyen JM, Quereux G, et al. CD13 and TCR clone: markers of early mycosis fungoides. Acta Dermatol Venereol. 2007;87(2):155–159. doi: 10.2340/00015555-0197</mixed-citation><mixed-citation xml:lang="ru">Bernier C., Nguyen J.M., Quereux G., et al. CD13 and TCR clone: markers of early mycosis fungoides // Acta Dermatol Venereol. 2007. Vol. 87, N 2. Р. 155–159. doi: 10.2340/00015555-0197</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Netchiporouk E, Litvinov IV, Moreau L, et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13(21):3331–3335. doi: 10.4161/15384101.2014.965061</mixed-citation><mixed-citation xml:lang="ru">Netchiporouk E., Litvinov I.V., Moreau L., et al. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression // Cell Cycle. 2014. Vol. 13, N 21. Р. 3331–3335. doi: 10.4161/15384101.2014.965061</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7):1288–1295. doi: 10.1038/sj.leu.2403385</mixed-citation><mixed-citation xml:lang="ru">Sommer V.H., Clemmensen O.J., Nielsen O., et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3 // Leukemia. 2004. Vol. 18, N 7. Р. 1288–1295. doi: 10.1038/sj.leu.2403385</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Litvinov I, Cordeiro B, Fredholm S, et al. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle. 2014;13(18):2975–2982. doi: 10.4161/15384101.2014.947759</mixed-citation><mixed-citation xml:lang="ru">Litvinov I., Cordeiro B., Fredholm S., et al. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines // Cell Cycle. 2014. Vol. 13, N 18. Р. 2975–2982. doi: 10.4161/15384101.2014.947759</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Nishikomori R, Usui T, Wu CY, et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12Rβ2 chain expression and signaling. J Immunol. 2002;169(8):4388–4398. doi: 10.4049/jimmunol.169.8.4388</mixed-citation><mixed-citation xml:lang="ru">Nishikomori R., Usui T., Wu C.Y., et al. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12Rβ2 chain expression and signaling // J Immunol. 2002. Vol. 169, N 8. Р. 4388–4398. doi: 10.4049/jimmunol.169.8.4388</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Paltsev MA, ed. Introduction to molecular diagnostics. Vol. 2. Moscow : Medicina; 2011. Р. 322–335. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Пальцев М.А., ред. Введение в молекулярную диагностику. Т. 2. Москва : Медицина, 2011. С. 322–335.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Yudin SV, Protasev VB, Podkopaev RYu, Yudin AS. Methodology of statistical acceptance control based on the Bayes approach (hypergeometric distribution). Modern High Technologies. 2018;(10):161–165. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Юдин С.В., Протасьев В.Б., Подкопаев Р.Ю., Юдин А.С. Методика статистического приемочного контроля на основе байесовского подхода (гипергеометрическое распределение) // Современные наукоемкие технологии. 2018. № 10. С. 161–165.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
